Listen to Dr. Kevin Punie and Prof. Evandro de Azambuja discussing the key results of the phase III OlympiA study, evaluating adjuvant olaparib in patients with BRCA-mutant early breast cancer
Dr. Kevin Punie (GZA Hospitals) and Prof. Evandro de Azambuja (Jules Bordet Institute)
This OncoTalk is brought to you by BJMO in partnership with AstraZeneca Belgium & Luxemburg, and MSD.
NS ID BE-3082-Revision date 02/2023-WEB
Tutt, Andrew N J et al. “Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.” N Engl J Med 2021; 384:2394-2405. doi:10.1056/NEJMoa2105215
SUBSCRIBE TO BJMO ONCOTALKS SERIES